ClinicalTrials.gg
CompletedNCT07936357Updated Nov 13, 2026

Mindfulness Program for Blood Sugar Control, Heart Rate Variability, Anxiety, and Depression in Type 2 Diabetes

An interventional study of Six-week audio-guided mindfulness program in Type 2 Diabetes Mellitus, Diabetic Autonomic Neuropathy and Anxiety, sponsored by Universitas Sebelas Maret Hospital. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Universitas Sebelas Maret Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Mar 2025, registered Nov 2026).
Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia — 9 open to participants now, 10 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Indonesia.

Enrollment
48th of 52
28 · median 85
Started
2025
with 6 others
No phase
25 of 66
3 open now
Registered
66th of 66
by date

Among the 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia, this one is the 48th largest by enrollment of the 52 interventional ones that give a count, is one of 7 that started in 2025, is one of 25 with no phase, and was the 66th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

9 of the 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia, or all of them as a file.
02

Study summary

The goal of this clinical trial was to learn whether a six-week mindfulness program, added to standard diabetes treatment, improves blood sugar control, heart rate variability (a measure of how the nervous system regulates the heart), anxiety, and depression in adults aged 18 to 60 years with type 2 diabetes. The main questions it aimed to answer were:

  • Does the mindfulness program lower glycated hemoglobin (HbA1c), fasting blood glucose, and 2-hour postprandial blood glucose?
  • Does it improve heart rate variability, cardiovascular autonomic dysfunction status, and anxiety and depression scores?

Researchers compared participants who received standard therapy plus the mindfulness program with participants who received standard therapy alone.

Participants in the mindfulness group listened to weekly audio-guided practices sent through WhatsApp (mindful eating, breathing exercise, body scan, mindful walking, dealing with unpleasant experiences, and loving-kindness meditation) and were asked to practice daily for six weeks. All participants had blood tests, a 3-minute heart rate variability recording, and the Hospital Anxiety and Depression Scale questionnaire at the start of the study and after six weeks.

Read the detailed description

This single-center, parallel-group randomized controlled trial with a pretest-posttest design was conducted at the Internal Medicine Outpatient Clinic of Dr. Moewardi General Hospital, Surakarta, Indonesia, from March to June 2025. Adults with type 2 diabetes receiving antidiabetic treatment were randomly allocated in a 1:1 ratio to standard therapy plus a six-week mindfulness program (intervention) or standard therapy alone (control).

The mindfulness program was adapted from a mindfulness-based stress reduction (MBSR) handbook and consisted of one theme per week: mindful eating, breathing exercise, body scan, staying present (mindful walking), dealing with unpleasant experiences, and loving-kindness meditation. Guided practices were delivered weekly as audio recordings through WhatsApp; participants were asked to practice daily (approximately 20 minutes per day) and received regular reminders.

Outcomes were assessed at baseline and after six weeks. HbA1c was measured with a point-of-care analyzer (Afinion HbA1c, Abbott); fasting and 2-hour postprandial venous blood glucose were measured with an enzymatic photometric method in the hospital laboratory. Short-term heart rate variability was recorded for 3 minutes with a fingertip photoplethysmographic sensor (SA-3000P, Medicore), and cardiovascular autonomic dysfunction was defined as three or more heart rate variability indices deviating by more than 2.5 standard deviations from the device reference values. Anxiety and depression were assessed with the Indonesian version of the Hospital Anxiety and Depression Scale.

The sample size (13 per group, increased to 14 per group to allow for 10% attrition; 28 in total) was calculated with OpenEpi (two-sided alpha 0.05, power 80%). Between-group comparisons used the independent t-test or Mann-Whitney U test, within-group comparisons used the paired t-test or Wilcoxon signed-rank test, and changes in autonomic dysfunction status were analyzed with the McNemar test.

03

Conditions studied

  • Type 2 Diabetes Mellitus
  • Diabetic Autonomic Neuropathy
  • Anxiety
  • Depression

Keywords

  • mindfulness
  • mindfulness-based stress reduction
  • meditation
  • heart rate variability
  • glycated hemoglobin
  • Hospital Anxiety and Depression Scale
  • Indonesia
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-60 years with type 2 diabetes mellitus
  • Receiving antidiabetic treatment
  • Attending the Internal Medicine Outpatient Clinic of Dr. Moewardi General Hospital
  • Willing to participate and provided written

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Thyroid disorders
  • Cardiac arrhythmia
  • Use of drugs that may affect heart rate variability (e.g., beta-blockers, antidepressants, antipsychotics, or anxiolytics)
  • Coffee consumption within 1 week before the start of the study
  • Anemia ( \<13 g/dL in men or \<12 g/dL in women)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Mindfulness plus standard therapy

    Participants continued their standard antidiabetic therapy and completed a six-week audio-guided mindfulness program delivered through WhatsApp.

    Behavioral: Six-week audio-guided mindfulness program

  • No intervention
    Standard therapy

    Participants continued their standard antidiabetic therapy without the mindfulness program.

Interventions

  • BehavioralSix-week audio-guided mindfulness program

    A six-week mindfulness program adapted from a mindfulness-based stress reduction (MBSR) handbook, with one theme per week: (1) mindful eating, (2) breathing exercise, (3) body scan, (4) staying present - mindful walking, (5) dealing with unpleasant experiences, and (6) loving-kindness meditation. Guided practices were delivered weekly as audio recordings through WhatsApp; participants practiced daily (approximately 20 minutes per day) and received regular reminders, in addition to standard antidiabetic therapy.

    Also known as: Mindfulness-based intervention, MBSR-based audio program

06

What researchers measure

Primary outcomes

  1. Change in glycated hemoglobin (HbA1c)

    HbA1c (%) measured with a point-of-care analyzer (Afinion HbA1c, Abbott). Change was calculated as the 6-week value minus the baseline value.

    Time frame: Baseline and 6 weeks

  2. Change in fasting blood glucose

    Venous blood glucose after an 8-10-hour fast, measured with an enzymatic photometric method (mg/dL). Change was calculated as the 6-week value minus the baseline value.

    Time frame: Baseline and 6 weeks

  3. Change in 2-hour postprandial blood glucose

    Venous blood glucose 2 hours after a meal, measured with an enzymatic photometric method (mg/dL). Change was calculated as the 6-week value minus the baseline value.

    Time frame: Baseline and 6 weeks

Secondary outcomes

  1. Change in standard deviation of normal-to-normal intervals (SDNN)

    Short-term heart rate variability (ms) from a 3-minute recording with a fingertip photoplethysmographic sensor (SA-3000P, Medicore). Change was calculated as the 6-week value minus the baseline value.

    Time frame: Baseline and 6 weeks

  2. Number of participants with cardiovascular autonomic dysfunction

    Cardiovascular autonomic dysfunction was defined as three or more heart rate variability indices deviating by more than 2.5 standard deviations from the device reference values.

    Time frame: Baseline and 6 weeks

  3. Change in Hospital Anxiety and Depression Scale - Anxiety (HADS-A) score

    HADS anxiety subscale, range 0-21; higher scores indicate more severe anxiety symptoms. Change was calculated as the 6-week value minus the baseline value.

    Time frame: Baseline and 6 weeks

  4. Change in Hospital Anxiety and Depression Scale - Depression (HADS-D) score

    HADS depression subscale, range 0-21; higher scores indicate more severe depressive symptoms. Change was calculated as the 6-week value minus the baseline value.

    Time frame: Baseline and 6 weeks

07

Study locations

1 site
  • Dr. Moewardi General Hospital
    Surakarta, Central Java 57126, Indonesia
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be made publicly available to protect participant privacy; de-identified data may be obtained from the principal investigator upon reasonable request.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Jun 2025, 3 months.

Of 2,068 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 3 months is below that.

Counting every sponsor, half of 2,245 studies reached it within 21 months; a quarter within 10 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2026
First posted
Nov 13, 2026
StartActual
Mar 1, 2025
Primary completionActual
Jun 30, 2025
CompletionActual
Jun 30, 2025
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07936357
Lead sponsor
Universitas Sebelas Maret Hospital
Collaborators
Universitas Sebelas Maret, Dr. Moewardi General Hospital
Responsible party
Sponsor
First posted
Nov 13, 2026
Start date
Mar 1, 2025
Primary completion
Jun 30, 2025
Completion
Jun 30, 2025
Last update
Nov 13, 2026

Study contacts

Farha Naily Fawzia, MD
principal investigator · Universitas Sebelas Maret

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion